Patient Portal

John F. DiPersio, MD, PhD

Virginia E. and Samuel J Golman Endowed Professorship of Medicine, Pathology & Immunology
Professor, Pediatrics
Professor, Pathology
Chief, Division of Oncology
Deputy Director, Siteman Cancer Center

Specialty Areas

Bone Marrow Transplant
Hematology
Leukemia
Hematologic Malignancies
Gene Therapy

Board Certifications

Hematology
Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Hematology, oncology, bone marrow transplantation, hematopoietic stem cell transplantation, molecular biology, cellular biology, leukemia, MDS, aplastic anemia

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-454-8304
Fax: 314-454-7551

Education

Education

Fellowship: Hematology & Oncology, UCLA School of Medicine, Los Angeles, CA 1987
Chief Resident: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1984
Residency: Internal Medicine, Parkland Memorial Hospital, Dallas, TX 1983
Ph.D.: Microbiology, University of Rochester School of Medicine, Rochester, NY 1980
Medical Degree: University Of Rochester School of Medicine, Rochester, NY 1980
B.A.: Biology, Williams College 1973

Publication & Research

Publication & Research

CiTE antibody for AML.
Rettig MP, DiPersio JF
Blood. 2018 Dec 6; 132(23)2425-2427. doi: 10.1182/blood-2018-10-879668.

PMID:
    30523124
    [PubMed - in process]
Related citations


Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD.
Ashami K, DiPersio JF, Choi J
Oncotarget. 2018 Nov 6; 9(87)35721-35722. doi: 10.18632/oncotarget.26291.

PMID:
    30515263
    [PubMed]
Related citations


Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation.
Alahmari B, Cooper M, Ziga E, Ritchey J, DiPersio JF, Choi J
PLoS One. 2018; 13(11)e0207609. doi: 10.1371/journal.pone.0207609.

PMID:
    30452487
    [PubMed - in process]
Related citations


Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF
N Engl J Med. 2018 Oct 31; doi: 10.1056/NEJMoa1808777.

PMID:
    30380364
    [PubMed - as supplied by publisher]
Related citations


Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, Wartman LD, Christopher MJ, Pusic I, Welch JS, Uy GL, Link DC, DiPersio JF, Westervelt P, Ley TJ, Trinkaus K, Graubert TA, Walter MJ
N Engl J Med. 2018 Sep 13; 379(11)1028-1041. doi: 10.1056/NEJMoa1804714.

PMID:
    30207916
    [PubMed - indexed for MEDLINE]
Related citations


Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE
Blood Cancer J. 2018 Sep 3; 8(9)88. doi: 10.1038/s41408-018-0122-3.

PMID:
    30190469
    [PubMed - in process]
Related citations


Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.
Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, DiPersio JF, Ghobadi A
Leuk Res. 2018 Sep; 7286-91. doi: 10.1016/j.leukres.2018.07.024.

PMID:
    30114560
    [PubMed - in process]
Related citations


Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L
Genome Med. 2018 Jul 27; 10(1)60. doi: 10.1186/s13073-018-0564-z.

PMID:
    30053901
    [PubMed - in process]
Related citations


Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
Gooptu M, Kim HT, Chen YB, Rybka W, Artz A, Boyer M, Johnston L, McGuirk J, Shea TC, Jagasia M, Shaughnessy PJ, Reynolds CG, Fields M, Alyea EP, Ho VT, Glavin F, Dipersio JF, Westervelt P, Ritz J, Soiffer RJ
Biol Blood Marrow Transplant. 2018 Nov; 24(11)2216-2223. doi: 10.1016/j.bbmt.2018.07.002.

PMID:
    30006305
    [PubMed - in process]
Related citations


Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance.
Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS
Immunity. 2018 Jun 19; 48(6)1271. doi: 10.1016/j.immuni.2018.05.011.

PMID:
    29924978
    [PubMed - in process]
Related citations


Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.
Huselton E, Slade M, Trinkaus KM, DiPersio JF, Westervelt P, Romee R
Biol Blood Marrow Transplant. 2018 Oct; 24(10)2047-2055. doi: 10.1016/j.bbmt.2018.05.024.

PMID:
    29803753
    [PubMed - in process]
Related citations


CD36 Mediates Cell-Surface Antigens to Promote Thymic Development of the Regulatory T Cell Receptor Repertoire and Allo-tolerance.
Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS
Immunity. 2018 May 15; 48(5)923-936.e4. doi: 10.1016/j.immuni.2018.04.007.

PMID:
    29752065
    [PubMed - in process]
Related citations


Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG
Mol Cancer Ther. 2018 Aug; 17(8)1739-1751. doi: 10.1158/1535-7163.MCT-17-1095.

PMID:
    29743205
    [PubMed - in process]
Related citations


Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.
Ghobadi A, Rettig MP, Holt MS, Ritchey JK, Kennerly K, Chendamarai E, Eissenberg L, DiPersio JF
Blood. 2018 Jun 7; 131(23)2594-2596. doi: 10.1182/blood-2017-10-811620.

PMID:
    29695518
    [PubMed - in process]
Related citations


Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, Marsala L, Niswonger J, Ritchey J, Alahmari B, Achilefu S, Tsunoda I, Schroeder MA, DiPersio JF
Leukemia. 2018 Nov; 32(11)2483-2494. doi: 10.1038/s41375-018-0123-z.

PMID:
    29691471
    [PubMed - in process]
Related citations


Pathogenic Germline Variants in 10,389 Adult Cancers.
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Cancer Genome Atlas Research Network., Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L
Cell. 2018 Apr 5; 173(2)355-370.e14. doi: 10.1016/j.cell.2018.03.039.

PMID:
    29625052
    [PubMed - in process]
Related citations


A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E
Biol Blood Marrow Transplant. 2018 Aug; 24(8)1581-1589. doi: 10.1016/j.bbmt.2018.03.019.

PMID:
    29597002
    [PubMed - in process]
Related citations


Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.
Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA
Haematologica. 2018 Jun; 103(6)e270-e273. doi: 10.3324/haematol.2017.184168.

PMID:
    29567774
    [PubMed - in process]
Related citations


A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH
Blood Cancer J. 2018 Mar 21; 8(3)35. doi: 10.1038/s41408-018-0062-y.

PMID:
    29563506
    [PubMed - in process]
Related citations


Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, Robinson J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Pusic I, Welch JS, Link DC, DiPersio JF, Westervelt P, Ley TJ, Graubert TA, Walter MJ
JCI Insight. 2018 Mar 8; 3(5)pii: 98962. doi: 10.1172/jci.insight.98962.

PMID:
    29515031
    [PubMed - as supplied by publisher]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: Magenta Therapeutics

Royalties:

Equity: Yes

Consulting/Advisory Board: $1 - $9,999

Speaker Fees:

Reporting Date: May 01, 2018